Scholar Rock (NASDAQ:SRRK) Insider Sells $193,425.21 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Jing Marantz sold 4,157 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $193,425.21. Following the transaction, the insider owned 126,012 shares of the company’s stock, valued at approximately $5,863,338.36. The trade was a 3.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Scholar Rock Stock Performance

SRRK stock traded up $0.74 during mid-day trading on Thursday, hitting $47.70. The company had a trading volume of 960,100 shares, compared to its average volume of 1,005,770. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The firm has a market cap of $4.87 billion, a PE ratio of -15.14 and a beta of 0.67. Scholar Rock Holding Corporation has a 12 month low of $22.71 and a 12 month high of $49.82. The stock’s fifty day moving average price is $45.12 and its two-hundred day moving average price is $38.23.

Hedge Funds Weigh In On Scholar Rock

A number of large investors have recently made changes to their positions in the stock. Moody Aldrich Partners LLC raised its stake in shares of Scholar Rock by 53.5% during the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock valued at $3,789,000 after purchasing an additional 35,481 shares during the period. Norges Bank bought a new position in Scholar Rock in the 2nd quarter worth about $41,628,000. Voya Investment Management LLC grew its holdings in Scholar Rock by 18.1% during the 3rd quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock valued at $16,503,000 after buying an additional 67,839 shares in the last quarter. Ensign Peak Advisors Inc increased its position in shares of Scholar Rock by 78.8% during the second quarter. Ensign Peak Advisors Inc now owns 600,639 shares of the company’s stock valued at $21,275,000 after buying an additional 264,693 shares during the period. Finally, Nan Fung Trinity HK Ltd. bought a new stake in shares of Scholar Rock during the third quarter valued at about $1,402,000. 91.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on SRRK. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. UBS Group started coverage on Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 target price on the stock. Barclays increased their price target on Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Wolfe Research began coverage on Scholar Rock in a report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, January 22nd. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $51.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).